Lesson plan
2CB-2-EtO
2CB-2-EtO, also known as 4-bromo-2-methoxy-5-ethoxyphenethylamine, is a psychedelic drug of the phenethylamine, 2C, and TWEETIO families related to 2C-B. It is the derivative of 2C-B in which the methoxy group at the 2 position has been replaced with an ethoxy group. According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, 2CB-2-EtO produces maximal effects at a dose of about 15 mg orally. Higher doses of 30 to 50 mg orally did not increase its effects any further but only prolonged their duration, from about 3 hours to perhaps 6 hours. 2CB-2-EtO was said to have not had an intensity that resembled that of 2C-B at any dose. It was also said to be dramatically or about 5-fold less potent than 2C-B. Beyond the preceding, the specific effects of 2CB-2-EtO were not described. The chemical synthesis of 2CB-2-EtO has been described. 2CB-2-EtO was first described in the literature by Shulgin in PiHKAL in 1991. It was developed and tested by Darrell Lemaire, with publication via personal communication with Shulgin. The drug is a controlled substance in Canada under phenethylamine blanket-ban language.
Article summary
2CB-2-EtO, also known as 4-bromo-2-methoxy-5-ethoxyphenethylamine, is a psychedelic drug of the phenethylamine, 2C, and TWEETIO families related to 2C-B. It is the derivative of 2C-B in which the methoxy group at the 2 position has been replaced with an ethoxy group. According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, 2CB-2-EtO produces maximal effects at a dose of about 15 mg orally. Higher doses of 30 to 50 mg orally did not increase its effects any further but only prolonged their duration, from about 3 hours to perhaps 6 hours. 2CB-2-EtO was said to have not had an intensity that resembled that of 2C-B at any dose. It was also said to be dramatically or about 5-fold less potent than 2C-B. Beyond the preceding, the specific effects of 2CB-2-EtO were not described. The chemical synthesis of 2CB-2-EtO has been described. 2CB-2-EtO was first described in the literature by Shulgin in PiHKAL in 1991. It was developed and tested by Darrell Lemaire, with publication via personal communication with Shulgin. The drug is a controlled substance in Canada under phenethylamine blanket-ban language.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.